Mounjaro alternatives in tablet form: what the UK evidence actually shows

Is there actually a tablet that does what Mounjaro does?

Mounjaro (tirzepatide) is a once-weekly subcutaneous injection and, as of mid-2026, there is no oral version of tirzepatide licensed in the UK for weight management. So the search for a 'Mounjaro tablet' doesn't have a like-for-like answer. What does exist is a different drug in tablet form: Wegovy tablets, which contain semaglutide, approved by the MHRA on 11 June 2026 as the first oral GLP-1 weight-management medicine in the UK.

Semaglutide works on one receptor pathway, the GLP-1 receptor, slowing gastric emptying and signalling fullness to the brain. If you want to understand how it compares to semaglutide, our tirzepatide page explains how it activates both the GLP-1 and GIP receptors, making it the only dual-agonist weight-loss medicine currently available in the UK. That difference in mechanism is partly why the trial results differ. In the SURMOUNT-1 study, tirzepatide at its highest dose produced around 20–21% average body-weight reduction over 72 weeks. The oral semaglutide trial (OASIS 4, 64 weeks) reported roughly 13.6% average loss overall, rising to about 17% among participants who remained fully adherent throughout.

Neither figure should be read as a personal forecast — both are population averages from controlled trials, and what you experience depends on your starting point, lifestyle changes and how you tolerate the medicine. A prescriber looks at the whole picture, not just the headline number. If you're weighing up the options, our guide to Mounjaro alternatives for weight loss covers the clinical comparison in more depth.

What makes taking a tablet different in practice, and who might prefer it?

For some people, the appeal of a tablet is straightforward: no needles, nothing to refrigerate, nothing to organise around cold-chain storage. Wegovy tablets are taken once daily, first thing in the morning on an empty stomach with a small amount of plain water, waiting at least 30 minutes before eating, drinking anything else or taking other oral medicines. They can be stored at room temperature, which makes travel (including longer trips where keeping a pen cold is genuinely difficult) less complicated.

The injection route has its own logic. The once-weekly schedule means one decision a week rather than one each morning, and the pen format is well-established across thousands of clinical-trial participants. The KwikPen that delivers Mounjaro, for example, has a straightforward mechanism that most people find manageable after the first injection or two.

One thing our prescribers hear from people who are reconsidering their current treatment: the timing of daily habits matters more than people expect. Taking a tablet every morning before breakfast, ideally before the kettle goes on, becomes second nature for many, but it does require a consistent routine. That's worth considering honestly before choosing a format.

From a safety infrastructure standpoint, both medicines carry the MHRA's Black Triangle (▼) designation, meaning they are subject to additional post-marketing monitoring. Both have a GI-led side-effect profile: nausea, vomiting, diarrhoea, constipation and indigestion are the most commonly reported effects, typically more noticeable when starting or after a dose increase. You can read the NHS's patient-level information on tirzepatide and semaglutide via the NHS medicines pages.

Does anything come close to being an over-the-counter tablet alternative?

No licensed GLP-1 medicine for weight loss is available without a prescription in the UK. Orlistat is the only weight-management medicine available over the counter in a lower-strength form (Alli, 60 mg), but it works by blocking fat absorption rather than acting on appetite-signalling hormones, and its results profile is substantially different. It is not a GLP-1 and is not comparable to either Mounjaro or Wegovy tablets.

It is worth being direct here: sellers advertising GLP-1 medicines (injections or tablets) without requiring a valid UK prescription are not operating legally. The MHRA has conducted large-scale enforcement action against illicit supply of these medicines, and fake or unregulated products have caused real harm. If a site or social-media account offers these medicines without clinical assessment, that is a red flag, not a shortcut.

For a fuller look at whether anything in the over-the-counter space genuinely serves as an alternative, our OTC alternatives explainer sets out the landscape honestly. And if you're still deciding between injection and tablet formats, the tablet alternative to Mounjaro page goes into the practical comparison in detail.

How does a prescriber decide which option is right for someone?

This is the question that actually matters, and it doesn't have a universal answer. Prescribers look at your BMI, any weight-related conditions, medication history, daily routine and your previous experience with weight-management treatment. Both Mounjaro and Wegovy tablets are licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

Someone already established on weekly semaglutide injections can, in principle, move directly to the 25 mg oral maintenance dose, but only under clinical supervision. Someone starting fresh might weigh the daily-tablet routine against the weekly-injection one based on their lifestyle, and our Mounjaro alternatives page can help you think through which approach suits your circumstances. Someone with a history of significant GI sensitivity might need a more gradual titration schedule on either medicine.

The detailed guide on Mounjaro alternatives addresses many of the specific scenarios people ask about. For a broader look at what licensed weight-loss treatments currently exist in the UK, the weight-loss treatments overview covers all options in one place.

If you want a prescriber to assess which option suits your specific situation, nume's clinical team reviews consultations the same working day they are submitted. There's no obligation, and the consultation is free. Speak to our prescribers to get a clinical view on whether Mounjaro, Wegovy tablets or another option is the right fit for you.